Product Description
Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and is under investigation as therapy of chronic hepatitis D. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lonafarnib)
Mechanisms of Action: FT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden | United States
Approved Indications: None
Known Adverse Events: None
Company: Eiger BioPharmaceuticals
Company Location:
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- FDA accepted Eiger's NDA for accelerated review of Zokinvy for progeria with a PDUFA target date of November 20, 2020.
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Liver Cirrhosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2018-003167-54 |
D-LIVR | P3 |
Completed |
Hepatocellular Carcinoma|Liver Cirrhosis |
2023-03-24 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |